Brain Penetrant LRRK2 Inhibitor.
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrimidine, HG-10-102-01(4) is a potent and selective inhibitor of wild-type LRRK2 and the G2019S mutant. Compound 4 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3 µM in cells and is the first compound reported to be capable of inhibiting Ser910 and Ser935 phosphorylation in mouse brain following intraperitoneal delivery of doses as low as 50 mg/kg.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA ; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 250 Longwood Ave, SGM 628, Boston, MA 02115, USA.
Hwan Geun
HG
Choi
Jinwei
J
Zhang
Xianming
X
Deng
John M
JM
Hatcher
Matthew P
MP
Patricelli
Zheng
Z
Zhao
Dario R
DR
Alessi
Nathanael S
NS
Gray